Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
Current Signal: SELL (auto-tracking)
2.46% $16.25
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 383.51 mill |
EPS: | 1.230 |
P/E: | 13.21 |
Earnings Date: | May 05, 2024 |
SharesOutstanding: | 23.60 mill |
Avg Daily Volume: | 0.317 mill |
RATING 2024-03-28 |
---|
A+ |
Strong Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Buy | |
Return On Asset: | Strong Buy | |
DE: | Buy | |
P/E: | Strong Buy | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE 13.21 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
0.06x |
Company: PE 13.21 | industry: PE 222.16 |
DISCOUNTED CASH FLOW VALUE |
---|
$6.25 (-61.55%) $-10.00 |
Date: 2024-03-29 |
Expected Trading Range (DAY) |
---|
$ 15.58 - 16.92 ( +/- 4.15%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-27 | Burns Kristie | Sell | 1 091 | Common Stock |
2024-02-29 | Burns Kristie | Sell | 243 | Common Stock |
2024-02-27 | Reuvers Daniel L. | Sell | 4 689 | Common Stock |
2024-02-29 | Reuvers Daniel L. | Sell | 1 396 | Common Stock |
2024-02-24 | Reuvers Daniel L. | Buy | 13 100 | Common Stock |
INSIDER POWER |
---|
80.68 |
Last 93 transactions |
Buy: 671 413 | Sell: 92 622 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $16.25 (2.46% ) |
Volume | 0.229 mill |
Avg. Vol. | 0.317 mill |
% of Avg. Vol | 72.11 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $15.01 | N/A | Active |
---|
Tactile Systems Technology, Inc., a medical technology company, engages in the development and provision of medical devices for chronic diseases in the United States. The company offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema; Entre system, a portable pneumatic compression device that is used for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers; and AffloVest, a portable high frequency chest wall oscillation test for the treatment of retained pulmonary secretions such as bronchiectasis, cystic fibrosis, and various neuromuscular disorders. The company was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.